Opioid Product Rights Regained By This Pharmaceutical Company

DMK Pharmaceuticals: Regaining Full Rights to ZIMHI, a Major Leap in the Pharma Industry.

In an exciting turn of events, DMK Pharmaceuticals Corporation (Nasdaq: DMK) has regained complete commercialization rights for ZIMHI® (naloxone), a product aimed at addressing opioid overdoses. This significant development positions DMK as a key player in the pharmaceutical industry, with full control over the commercialization and distribution of ZIMH…